Piper Sandler Reiterates Overweight on TransMedics Gr, Maintains $180 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Matt O'Brien has reiterated an Overweight rating on TransMedics Group (NASDAQ:TMDX) and maintained a price target of $180.
October 29, 2024 | 4:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has reiterated an Overweight rating for TransMedics Group, maintaining a price target of $180, indicating confidence in the company's future performance.
The reiteration of an Overweight rating and a maintained price target of $180 by Piper Sandler suggests a positive outlook for TransMedics Group. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100